CN103923075A - 新型链状二萜类化合物的制备与应用 - Google Patents
新型链状二萜类化合物的制备与应用 Download PDFInfo
- Publication number
- CN103923075A CN103923075A CN201310014885.6A CN201310014885A CN103923075A CN 103923075 A CN103923075 A CN 103923075A CN 201310014885 A CN201310014885 A CN 201310014885A CN 103923075 A CN103923075 A CN 103923075A
- Authority
- CN
- China
- Prior art keywords
- preparation
- tablet
- liquid chromatography
- chromatography
- concentrated
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 9
- -1 diterpenoid compounds Chemical class 0.000 title abstract 3
- 238000000034 method Methods 0.000 claims abstract description 8
- 238000000926 separation method Methods 0.000 claims abstract description 6
- 239000002246 antineoplastic agent Substances 0.000 claims abstract description 4
- 229940041181 antineoplastic drug Drugs 0.000 claims abstract description 4
- 150000001875 compounds Chemical class 0.000 claims description 13
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 12
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims description 8
- 240000000233 Melia azedarach Species 0.000 claims description 7
- 239000000284 extract Substances 0.000 claims description 7
- 238000002474 experimental method Methods 0.000 claims description 6
- 239000003814 drug Substances 0.000 claims description 5
- 238000000338 in vitro Methods 0.000 claims description 5
- 239000000203 mixture Substances 0.000 claims description 5
- 230000001093 anti-cancer Effects 0.000 claims description 4
- SRCZQMGIVIYBBJ-UHFFFAOYSA-N ethoxyethane;ethyl acetate Chemical compound CCOCC.CCOC(C)=O SRCZQMGIVIYBBJ-UHFFFAOYSA-N 0.000 claims description 4
- 239000003208 petroleum Substances 0.000 claims description 4
- 206010028980 Neoplasm Diseases 0.000 claims description 3
- 230000000118 anti-neoplastic effect Effects 0.000 claims description 3
- 238000004128 high performance liquid chromatography Methods 0.000 claims description 3
- 239000002904 solvent Substances 0.000 claims description 3
- 201000011510 cancer Diseases 0.000 claims description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 2
- 239000000499 gel Substances 0.000 claims description 2
- 238000010898 silica gel chromatography Methods 0.000 claims description 2
- 229940023488 pill Drugs 0.000 claims 3
- 239000006187 pill Substances 0.000 claims 3
- 239000000243 solution Substances 0.000 claims 2
- 238000004458 analytical method Methods 0.000 claims 1
- 238000003556 assay Methods 0.000 claims 1
- 239000002775 capsule Substances 0.000 claims 1
- 210000004027 cell Anatomy 0.000 claims 1
- 239000007910 chewable tablet Substances 0.000 claims 1
- 229940068682 chewable tablet Drugs 0.000 claims 1
- 238000004587 chromatography analysis Methods 0.000 claims 1
- 239000007919 dispersible tablet Substances 0.000 claims 1
- 239000007938 effervescent tablet Substances 0.000 claims 1
- 238000002481 ethanol extraction Methods 0.000 claims 1
- 238000001641 gel filtration chromatography Methods 0.000 claims 1
- 239000008187 granular material Substances 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 238000002347 injection Methods 0.000 claims 1
- 239000007924 injection Substances 0.000 claims 1
- 238000007689 inspection Methods 0.000 claims 1
- 238000004811 liquid chromatography Methods 0.000 claims 1
- XELZGAJCZANUQH-UHFFFAOYSA-N methyl 1-acetylthieno[3,2-c]pyrazole-5-carboxylate Chemical compound CC(=O)N1N=CC2=C1C=C(C(=O)OC)S2 XELZGAJCZANUQH-UHFFFAOYSA-N 0.000 claims 1
- 239000012046 mixed solvent Substances 0.000 claims 1
- 239000006191 orally-disintegrating tablet Substances 0.000 claims 1
- 238000004262 preparative liquid chromatography Methods 0.000 claims 1
- 239000007901 soft capsule Substances 0.000 claims 1
- 239000006188 syrup Substances 0.000 claims 1
- 235000020357 syrup Nutrition 0.000 claims 1
- 239000003826 tablet Substances 0.000 claims 1
- 210000004881 tumor cell Anatomy 0.000 claims 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 1
- 240000003906 Aphanamixis grandifolia Species 0.000 abstract description 2
- 230000001472 cytotoxic effect Effects 0.000 abstract description 2
- 238000012404 In vitro experiment Methods 0.000 abstract 1
- 229930045534 Me ester-Cyclohexaneundecanoic acid Natural products 0.000 description 12
- LZXAHLRMHMCWBP-KGSIEIPGSA-N [(3s,9r,10r,13s,14s,17r)-17-[(2s,3s,5r)-5-[(2r)-3,3-dimethyloxiran-2-yl]-2-hydroxyoxolan-3-yl]-4,4,10,13,14-pentamethyl-2,3,5,6,9,11,12,15,16,17-decahydro-1h-cyclopenta[a]phenanthren-3-yl] acetate Chemical compound O([C@@H]1[C@H]2C[C@H]([C@H](O2)O)[C@@H]2[C@]3(C)CC[C@@H]4[C@@]5(C)CC[C@@H](C(C5CC=C4[C@@]3(C)CC2)(C)C)OC(=O)C)C1(C)C LZXAHLRMHMCWBP-KGSIEIPGSA-N 0.000 description 12
- LZXAHLRMHMCWBP-UHFFFAOYSA-N aphanamixin Natural products C1CC2(C)C3=CCC4C(C)(C)C(OC(=O)C)CCC4(C)C3CCC2(C)C1C(C(O1)O)CC1C1OC1(C)C LZXAHLRMHMCWBP-UHFFFAOYSA-N 0.000 description 12
- 230000000259 anti-tumor effect Effects 0.000 description 6
- 239000000126 substance Substances 0.000 description 5
- 241001156421 Aphanamixis Species 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- 150000004141 diterpene derivatives Chemical class 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 238000001228 spectrum Methods 0.000 description 3
- 241000196324 Embryophyta Species 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 241000158728 Meliaceae Species 0.000 description 2
- REAYFGLASQTHKB-UHFFFAOYSA-N [2-[3-(1H-pyrazol-4-yl)phenoxy]-6-(trifluoromethyl)pyridin-4-yl]methanamine Chemical compound N1N=CC(=C1)C=1C=C(OC2=NC(=CC(=C2)CN)C(F)(F)F)C=CC=1 REAYFGLASQTHKB-UHFFFAOYSA-N 0.000 description 2
- 238000002512 chemotherapy Methods 0.000 description 2
- 238000004440 column chromatography Methods 0.000 description 2
- 239000000470 constituent Substances 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- MPDDTAJMJCESGV-CTUHWIOQSA-M (3r,5r)-7-[2-(4-fluorophenyl)-5-[methyl-[(1r)-1-phenylethyl]carbamoyl]-4-propan-2-ylpyrazol-3-yl]-3,5-dihydroxyheptanoate Chemical compound C1([C@@H](C)N(C)C(=O)C2=NN(C(CC[C@@H](O)C[C@@H](O)CC([O-])=O)=C2C(C)C)C=2C=CC(F)=CC=2)=CC=CC=C1 MPDDTAJMJCESGV-CTUHWIOQSA-M 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 230000001887 anti-feedant effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 229940125904 compound 1 Drugs 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- GBMDVOWEEQVZKZ-UHFFFAOYSA-N methanol;hydrate Chemical compound O.OC GBMDVOWEEQVZKZ-UHFFFAOYSA-N 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- AICOOMRHRUFYCM-ZRRPKQBOSA-N oxazine, 1 Chemical compound C([C@@H]1[C@H](C(C[C@]2(C)[C@@H]([C@H](C)N(C)C)[C@H](O)C[C@]21C)=O)CC1=CC2)C[C@H]1[C@@]1(C)[C@H]2N=C(C(C)C)OC1 AICOOMRHRUFYCM-ZRRPKQBOSA-N 0.000 description 1
- 239000000419 plant extract Substances 0.000 description 1
- 235000020245 plant milk Nutrition 0.000 description 1
- 239000003223 protective agent Substances 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 230000003595 spectral effect Effects 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 238000004809 thin layer chromatography Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
- C07D407/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Mycology (AREA)
- Health & Medical Sciences (AREA)
- Nutrition Science (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
本发明涉及六个新型链状二萜类化合物的制备方法及应用，包括该类成分从山楝中分离，体外试验证实这六个新型链状二萜类化合物具有显著细胞毒活性，可作为抗肿瘤药物的应用。
Description
技术领域
本发明涉及六个新型链状二萜类化合物的制备方法及应用，包括该类成分从山楝中分离，体外试验证实这六个新型链状二萜类化合物具有显著细胞毒活性，可作为抗肿瘤药物的应用。
背景技术：
肿瘤是目前危害人民生命和健康的严重疾病之一，目前，治疗癌症的方法主要包括手术、放疗、化疗、免疫治疗、中医中药治疗等多种。化疗主要依靠化学药物，而化学药物产生的耐药性以及毒副作用，亟待新型抗肿瘤药物的发现。天然药物富含多种结构新颖且活性显著的抗肿瘤化合物，引起世界范围的广泛关注。因此，从天然药物中寻找高效、低毒的抗癌活性成分一直是化学家和药理学家关注热点。山楝为(Aphanamixis polystachya)为楝科(Meliaceae)山楝属(Aphanamixis)植物，主要分布于广东、广西、云南等省的低海拔至中海拔山地沟谷密林或疏林中。文献报道该植物提取物具有昆虫拒食、防护剂的作用。我们在前期的体外抗肿瘤实验筛选时发现，其醇提取物具有显著性的抗肿瘤活性。通过深入研究，确定了抗肿瘤活性部位，并确定了该活性部位主要由6个新颖的二萜类成分组成，这些成分为：Aphanamixin A(1)，Aphanamixin B(2)，Aphanamixin C(3)，Aphanamixin D(4)，Aphanamixin E(5)，Aphanamixin F(6)。迄今为止，这些研究成果尚未有专利或文献报道。
本发明的有益效果和意义在于：本发明之目的在于充分利用我国丰富的山楝植物资源，深入进行研究开发，明确该该植物有效部位的组成及其制剂的临床应用，即该药用植物提取物由8二萜类成分组成，该提取物具有显著的体外抗肿瘤活性，以期为临床提供一种抗癌的现代中药制剂。
发明内容
1.本实验室利用现代分离技术和结构测定手段对楝科山楝属山楝抗肿瘤活性部位进行化学成分研究过程中，从中分离得到8个二萜类成分，分别为Aphanamixin A(1)，Aphanamixin B(2)，Aphanamixin C(3)，Aphanamixin D(4)，Aphanamixin E(5)，Aphanamixin F(6)。
附图说明
图1化合物1-6的化学结构
具体实施方式
根据本发明所公开的技术内容，本领域技术人员将很清楚本发明的其他实施方案，下述实施方案仅作示例。在不违反本发明主旨及范围的情况下，可对本发明进行各种改变和改进。这些改变和改进均应在本发明的保护范围之内。
实施案例(一)
取山楝茎皮2Kg，阴干后粉碎，醇类溶剂进行提取。提取液经浓缩至无醇味后，得到提取液。提取液经有机溶剂分配法进行萃取，分别采用石油醚、氯仿和乙酸乙酯进行萃取，浓缩萃取液后得分别到萃取部位B、C、D。其中部位C经体外实验发现具有显著地抗肿瘤活性，结果见表2。进一步对部位C进行系统分离，利用薄层色谱发对部位C进行分离条件选择，经过大量实验发现在石油醚-乙酸乙酯体系下，分离效果较好。以此，利用硅胶柱色谱进行粗分离，经过柱色谱粗分离后共收集8个流份(Fr.I-VIII)。Fr.II经凝胶柱色谱分离，氯仿∶甲醇1∶1体系洗脱，收集洗脱液，浓缩后得到不同的流份。利用高效液相色谱法对不同流份进行分离，采用甲醇-水不同体积比的溶剂进行洗脱，收集液相色谱图中为单峰的色谱峰，浓缩收集的洗脱液，得到化合物1；化合物2-8分别从Fr.III-Fr.VIII中分离得到，分离流程同化合物1。应用波谱学技术对化合物的结构进行鉴定，结果化合物1-6均为结构新颖的二萜类化合物。它们的化学结构见图1，波谱数据见表1和表2。
表1化合物1-3的核磁共振波谱数据
表2化合物4-6的核磁共振波谱数据
实施案例(二)
取对数生长期的细胞以每孔3×103～5×103个细胞接种于96孔板中培养24h后，小心吸出原培养基，加入含有不同浓度化合物(0.9375、1.875、3.75、7.5、15.0、30μmol·mL-1)的培养基200μL，对照组加入RPMI1640或DMEM培养基200μL。每组各设3个平行孔。将96孔板置37℃、5％CO2的恒温培养箱中培养48h。然后于每孔中加入20μLMTT(5mg·mL-1)，再培养2～3h，弃上清液，每孔加入150μL DMSO，振荡15min，应用酶标仪于570nm处测OD值，再计算出化合物的IC50。为确保结果的可靠性及实验的稳定性，所有实验在相同条件下重复进行3次。测试结果如表3。
表3山楝活性部位及化合物的抗肿瘤活性
a阳性药 。
Claims (8)
1.制备六个新型链状二萜类化合物的方法，该方法包括如下步骤：
(1)山楝乙醇提取物用氯仿和/或甲醇溶解；
(2)将步骤(1)中所得的溶液经硅胶柱色谱分离，依次用石油醚，石油醚-乙酸乙酯(9∶1)，石油醚-乙酸乙酯(4∶1)，石油醚-乙酸乙酯(2∶1)洗脱，洗脱液浓缩，依次得到不同极性的洗脱物；
(3)将步骤(2)中得到的洗脱物，溶解后经凝胶柱层析，用氯仿∶甲醇的体积比为1∶1的溶剂进行洗脱，并收集洗脱液；
(4)将步骤(3)中的洗脱液浓缩，经色谱检识合并，进一步得到不同的流份；
(5)将步骤(4)所得流份进行高效液相色谱分离，利用水∶甲醇不同体积比的混合溶剂进行洗脱，得到本发明中的六个新型化合物。
2.根据权利要求1所述，采用MTT法进行体外抗肿瘤实验，所用的五种细胞株分别为HepG2、KB-3-1、NCI-H460、MCF-7、A-549。
3.根据权利2要求的方法，上述步骤中所使用的凝胶柱为Sephadex LH-20柱。
4.根据权利2要求的方法，所述方法中高效液相色谱为分析型液相色谱或制备型液相色谱，配备半制备型色谱柱或制备型色谱柱。
5.权利要求1所述组合物具有显著的抑制肿瘤细胞生长活性，该提取物及其制剂可用于抗肿瘤药物的制备。
6.一种具有抗肿瘤的组合物，含有只有一种权利要求1的化合物。
7.权利要求1所述组合物在制备辅助治疗癌症有关疾病的保健品中的应用。
8.根据权利要求5所述的抗肿瘤的药物，其特征在于：所述的药物为胶囊(软胶囊)、颗粒剂(干混悬剂)、片剂(分散片、泡腾片、咀嚼片、口崩片)、溶液剂(糖浆)、丸剂(浓缩丸、滴丸、微丸)，或者为注射剂型。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310014885.6A CN103923075A (zh) | 2013-01-16 | 2013-01-16 | 新型链状二萜类化合物的制备与应用 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310014885.6A CN103923075A (zh) | 2013-01-16 | 2013-01-16 | 新型链状二萜类化合物的制备与应用 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN103923075A true CN103923075A (zh) | 2014-07-16 |
Family
ID=51141491
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201310014885.6A Pending CN103923075A (zh) | 2013-01-16 | 2013-01-16 | 新型链状二萜类化合物的制备与应用 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103923075A (zh) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108037212A (zh) * | 2017-12-27 | 2018-05-15 | 济南昊雨青田医药技术有限公司 | 一种治疗肺癌提取物的检测方法 |
-
2013
- 2013-01-16 CN CN201310014885.6A patent/CN103923075A/zh active Pending
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108037212A (zh) * | 2017-12-27 | 2018-05-15 | 济南昊雨青田医药技术有限公司 | 一种治疗肺癌提取物的检测方法 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN105348192B (zh) | 一种翅荚决明中抗病毒活性的异喹啉生物碱类化合物及其制备方法 | |
| CN103086882B (zh) | 对叶大戟果实中的大环二萜类化合物及其制备方法和用途 | |
| CN101824067A (zh) | 玉蕊醇型三萜皂苷类化合物、制备方法及其应用 | |
| CN104817432A (zh) | 一种二萜类化合物的抗肿瘤药物及其方法用途 | |
| CN102000066A (zh) | 水朝阳旋覆花提取物,以其为有效成分的抗肿瘤药物及其制备方法和应用 | |
| CN105198951B (zh) | 一种四环二萜类化合物及其制备方法与应用 | |
| CN104387362A (zh) | 一种环烯醚萜酯类化合物、其制备方法以及应用 | |
| CN105198943B (zh) | 一种名为茶山奈苷a的酰化黄酮糖苷及其制备方法和应用 | |
| CN103965157B (zh) | 一种二倍半萜内酯类化合物的制备方法 | |
| CN102178725B (zh) | 黄花草木犀总皂苷及其制备方法和药物用途 | |
| CN103923075A (zh) | 新型链状二萜类化合物的制备与应用 | |
| CN101721434B (zh) | 一种阿里红有效组分及其制备方法和用途 | |
| CN105801634B (zh) | 核桃青皮中一种直链醇苷化合物的制备方法和应用 | |
| CN105218320B (zh) | 一种对映‑贝壳杉烷型二萜化合物及其制备方法和应用 | |
| CN103479723A (zh) | 丹参二萜醌有效部位及其逆流色谱制备方法和癌症治疗应用 | |
| CN104138368A (zh) | 高良姜地上部分ao-95制备方法及其对癌症的治疗作用 | |
| CN103833818B (zh) | 一种油茶皂苷化合物、其制备方法、应用及其制备的抗肿瘤药物 | |
| CN101940615A (zh) | 尾叶香茶菜总二萜的制备新方法 | |
| CN104490986B (zh) | 一种甘遂活性组分及其制备方法与应用 | |
| CN105820044B (zh) | 一种新型c22二萜化合物及其制备方法和应用 | |
| CN105669692B (zh) | 一种苯酞类二聚体化合物的提取方法和用途 | |
| CN110183460A (zh) | 绵萆薢菲类化合物及应用和提取方法 | |
| CN103739657B (zh) | 一种油茶皂苷化合物、其制备方法、应用及其制备的抗肿瘤药物 | |
| CN101323569B (zh) | 倍半萜青蒿萜酯ae及其提取纯化方法 | |
| CN103800308B (zh) | 环菠萝蜜烷型降三萜在制备抗肿瘤药物中的用途 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20140716 |